What next after successful HIV injectable research?
The study, which is sponsored by Gilead sciences, was also known as Purpose 1 and it was conducted among 5,345 adolescent girls and young women aged 16–26 years at 25 sites in South Africa and three in Uganda.
PREMIUM Health
Charles Brown, the executive director of Preventive Care International, a non-government organisation based in Kanyanya in Kampala.
By NewVision Reporter
Journalists @NewVision
_______________
What next after the success of the twice-yearly HIV injectable pre-exposure prophylaxis (PreP) study whose results were released last month?
This is the question that key stakeholders in the